Immix Biopharma, Inc. (IMMX) has released an update to notify the public and investors about an entry into a material definitive agreement.
Immix Biopharma, Inc. has partnered with Titan Partners Group for an underwritten offering of over 5.5 million shares at $2.71 each, aiming to raise $15 million before fees and expenses. The deal includes an option for additional shares and is set to close by February 8, 2024, with conditions and customary closing provisions. Additionally, the company’s executives have agreed to a lock-up period restricting stock sales until May 2024.
For further insights into IMMX stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
